Advertisement

Topics

JMP $KPTI presented updated data including overall survival (OS) from Part II of the Phase IIb STORM study of selinexor in patients with penta-refractory multiple myeloma (MM) at Society of Hematologic Oncology (SOHO) Annual Meeting in Houston; reiterate

16:43 EDT 14 Sep 2018 | tgtxdough

JMP presented updated data including overall survival (OS) from Part II of the Phase IIb STORM study of selinexor in patients with penta-refractory multiple myeloma (MM) at Society of Hematologic Oncology (SOHO) Annual Meeting in Houston; reiterate Market Outperform 26 PT

Original Article: JMP $KPTI presented updated data including overall survival (OS) from Part II of the Phase IIb STORM study of selinexor in patients with penta-refractory multiple myeloma (MM) at Society of Hematologic Oncology (SOHO) Annual Meeting in Houston; reiterate

NEXT ARTICLE

More From BioPortfolio on "JMP $KPTI presented updated data including overall survival (OS) from Part II of the Phase IIb STORM study of selinexor in patients with penta-refractory multiple myeloma (MM) at Society of Hematologic Oncology (SOHO) Annual Meeting in Houston; reiterate "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...